The National Comprehensive Cancer Network issued updated guidelines for prostate cancer, including new information about the role of family history, specific mutations, and microsatellite instability testing.
The American Society of Clinical Oncology and the National Comprehensive Cancer Network have collaborated for the first time to release new clinical guidelines for managing immunotherapy-related toxicities.
The National Comprehensive Cancer Network updated their induction and consolidation treatment recommendations for low-risk and high-risk acute myeloid leukemia.
The National Comprehensive Cancer Network revised their criteria for discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Despite a trend toward increased metric use, approximately 50% of patients with RA are not routinely assessed with a disease activity metric, according to the results of a recent survey.
The National Comprehensive Cancer Network released new additions to their guidelines for bladder cancer, including changes to systemic therapy, primary treatments, and adjuvant treatments.
The National Comprehensive Cancer Network recently provided a few major updates to their palliative care guidelines.
The NCCN has issued updates to their guidelines for Hodgkin lymphoma, including additions to maintenance therapy options, systemic therapy options, and various treatment algorithms.
Nearly one in five women with early-stage breast cancer received guideline-discordant treatment, usually with regards to chemotherapy use.
Guideline-based management approaches can improve quality of care and outcomes for patients with heart failure and arrhythmic complications.